211 related articles for article (PubMed ID: 9207459)
1. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma.
Gascoyne RD; Adomat SA; Krajewski S; Krajewska M; Horsman DE; Tolcher AW; O'Reilly SE; Hoskins P; Coldman AJ; Reed JC; Connors JM
Blood; 1997 Jul; 90(1):244-51. PubMed ID: 9207459
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of Bax protein expression in diffuse aggressive non-Hodgkin's lymphoma.
Gascoyne RD; Krajewska M; Krajewski S; Connors JM; Reed JC
Blood; 1997 Oct; 90(8):3173-8. PubMed ID: 9376600
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study.
Hill ME; MacLennan KA; Cunningham DC; Vaughan Hudson B; Burke M; Clarke P; Di Stefano F; Anderson L; Vaughan Hudson G; Mason D; Selby P; Linch DC
Blood; 1996 Aug; 88(3):1046-51. PubMed ID: 8704213
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: an analysis of 83 cases.
Tang SC; Visser L; Hepperle B; Hanson J; Poppema S
J Clin Oncol; 1994 Jan; 12(1):149-54. PubMed ID: 8270971
[TBL] [Abstract][Full Text] [Related]
5. Correlation between EBV DNA and rearrangement and expression of Bcl-2 gene in aggressive non-Hodgkin's lymphoma.
Eissa S; Kassim SK; Imam M; Khalifa A
IUBMB Life; 1999 Aug; 48(2):231-6. PubMed ID: 10794603
[TBL] [Abstract][Full Text] [Related]
6. De novo nodal diffuse large B-cell lymphoma: identification of biologic prognostic factors.
Abd El-Hameed A
J Egypt Natl Canc Inst; 2005 Mar; 17(1):20-8. PubMed ID: 16353079
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.
Sohn SK; Jung JT; Kim DH; Kim JG; Kwak EK; Park Ti; Shin DG; Sohn KR; Lee KB
Am J Hematol; 2003 Jun; 73(2):101-7. PubMed ID: 12749011
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma.
Kramer MH; Hermans J; Wijburg E; Philippo K; Geelen E; van Krieken JH; de Jong D; Maartense E; Schuuring E; Kluin PM
Blood; 1998 Nov; 92(9):3152-62. PubMed ID: 9787151
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of bcl-2 (MBR)/JH rearrangement in the peripheral blood of patients with diffuse large B-cell lymphomas.
Zucca E; Bertoni F; Bosshard G; Roggero E; Ceresa E; Sanna P; Pedrinis E; Cavalli F
Ann Oncol; 1996 Dec; 7(10):1023-7. PubMed ID: 9037360
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Hermine O; Haioun C; Lepage E; d'Agay MF; Briere J; Lavignac C; Fillet G; Salles G; Marolleau JP; Diebold J; Reyas F; Gaulard P
Blood; 1996 Jan; 87(1):265-72. PubMed ID: 8547651
[TBL] [Abstract][Full Text] [Related]
11. Frequency of bcl-2 gene rearrangement in B-cell Non-Hodgkin's lymphoma.
Arif A; Jamal S; Mushtaq S; Ahmed S; Mubarik A
Asian Pac J Cancer Prev; 2009; 10(2):237-40. PubMed ID: 19537891
[TBL] [Abstract][Full Text] [Related]
12. Bcl-2 rearrangements with breakpoints in both vcr and mbr in non-Hodgkin's lymphomas and chronic lymphocytic leukaemia.
Merup M; Spasokoukotskaja T; Einhorn S; Smith CI; Gahrton G; Juliusson G
Br J Haematol; 1996 Mar; 92(3):647-52. PubMed ID: 8616030
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of t(14;18) and bcl-2 gene expression in follicular small cleaved cell lymphoma and diffuse large cell lymphoma.
Martinka M; Comeau T; Foyle A; Anderson D; Greer W
Clin Invest Med; 1997 Dec; 20(6):364-70. PubMed ID: 9413633
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2 gene rearrangement in Jordanian follicular and diffuse large B-cell lymphomas.
Almasri NM; Al-Alami J; Faza M
Saudi Med J; 2005 Feb; 26(2):251-5. PubMed ID: 15770300
[TBL] [Abstract][Full Text] [Related]
15. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
16. MBR rearrangement and P-glycoprotein expression are not independent prognostic factors like p53 protein in malignant lymphoma.
Sun RX; Coste J; Segara C; Rousset T; Fabbro M; Rème T; Legouffe E; Klein B; Rossi JF
Clin Lab Haematol; 1998 Apr; 20(2):87-94. PubMed ID: 9681218
[TBL] [Abstract][Full Text] [Related]
17. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma.
López-Guillermo A; Cabanillas F; McDonnell TI; McLaughlin P; Smith T; Pugh W; Hagemeister F; Rodríguez MA; Romaguera JE; Younes A; Sarris AH; Preti HA; Lee MS
Blood; 1999 May; 93(9):3081-7. PubMed ID: 10216105
[TBL] [Abstract][Full Text] [Related]
18. [Clinical characteristics and prognosis of concurrent positive t(14; 18) and myc gene rearrangement in diffuse large B cell lymphoma].
Zhang HW; Chen ZW; Wang LY; He JX; Zheng YP; Han WE; Yang B; Wang YL; Zhao ZQ; Bai M; Su LP
Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):206-10. PubMed ID: 26988827
[TBL] [Abstract][Full Text] [Related]
19. Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients.
Vitolo U; Gaidano G; Botto B; Volpe G; Audisio E; Bertini M; Calvi R; Freilone R; Novero D; Orsucci L; Pastore C; Capello D; Parvis G; Sacco C; Zagonel V; Carbone A; Mazza U; Palestro G; Saglio G; Resegotti L
Ann Oncol; 1998 Jan; 9(1):55-61. PubMed ID: 9541684
[TBL] [Abstract][Full Text] [Related]
20. An immunophenotypic and molecular study of primary large B-cell lymphoma of bone.
Huebner-Chan D; Fernandes B; Yang G; Lim MS
Mod Pathol; 2001 Oct; 14(10):1000-7. PubMed ID: 11598170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
